Trastuzumab after adjuvant chemotherapy: survival benefit in HER2-positive breast cancer
This article has no abstract so we have provided the first paragraph of the full text.
Administration of trastuzumab after chemotherapy has been shown to improve disease-free survival in patients with HER2-positive early-stage breast cancer. The Herceptin Adjuvant (HERA) study investigators have explored whether this humanized monoclonal antibody, which targets HER, also improves overall survival. Results after 2 years of follow-up are positive, showing a considerable overall survival benefit for women receiving trastuzumab.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.